Concizumab
Concizumab (pronounced: con-ciz-u-mab) is a novel investigational anticoagulant drug developed by Novo Nordisk. It is a monoclonal antibody that targets the tissue factor pathway inhibitor (TFPI), a protein involved in the regulation of blood clotting.
Etymology
The name "Concizumab" is derived from the Latin word "concisus", meaning "cut off", and "mab", a common suffix for monoclonal antibodies. The name reflects the drug's mechanism of action, which involves inhibiting a protein that normally prevents blood clotting, thereby "cutting off" this inhibitory effect.
Mechanism of Action
Concizumab works by binding to and inhibiting the tissue factor pathway inhibitor (TFPI), a protein that normally prevents blood clotting. By inhibiting TFPI, Concizumab allows for increased clotting activity, which can help prevent bleeding in patients with certain bleeding disorders.
Clinical Trials
Concizumab has been studied in several clinical trials for its potential use in treating bleeding disorders such as hemophilia. These trials have shown promising results, with patients receiving Concizumab experiencing fewer bleeding episodes compared to those receiving placebo.
Related Terms
See Also
External links
- Medical encyclopedia article on Concizumab
- Wikipedia's article - Concizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski